Vigabatrin‐associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex
Carmen Stevering,Maarten Lequin,Kinga Szczepaniak,Krzysztof Sadowski,Saba Ishrat,Alberto De Luca,Alexander Leemans,Willem Otte,David J. Kwiatkowski,Paolo Curatolo,Bernhard Weschke,Kate Riney,Martha Feucht,Pavel Krsek,Rima Nabbout,Anna Jansen,Konrad Wojdan,Kamil Sijko,Jagoda Glowacka‐Walas,Julita Borkowska,Dorota Domanska‐Pakiela,Romina Moavero,Christoph Hertzberg,Hanna Hulshof,Theresa Scholl,Bořivoj Petrák,Miroslav Maminak,Eleonora Aronica,Jessie De Ridder,Lieven Lagae,Sergiusz Jozwiak,Katarzyna Kotulska,Kees Braun,Floor Jansen
DOI: https://doi.org/10.1111/epi.18190
IF: 6.74
2024-12-08
Epilepsia
Abstract:Objective Previous retrospective studies have reported vigabatrin‐associated brain abnormalities on magnetic resonance imaging (VABAM), although clinical impact is unknown. We evaluated the association between vigabatrin and predefined brain magnetic resonance imaging (MRI) changes in a large homogenous tuberous sclerosis complex (TSC) cohort and assessed to what extent VABAM‐related symptoms were reported in TSC infants. Methods The Dutch TSC Registry and the EPISTOP cohort provided retrospective and prospective data from 80 TSC patients treated with vigabatrin (VGB) before the age of 2 years and 23 TSC patients without VGB. Twenty‐nine age‐matched non‐TSC epilepsy patients not receiving VGB were included as controls. VABAM, specified as T2/fluid‐attenuated inversion recovery hyperintensity or diffusion restriction in predefined brain areas, were examined on brain MRI before, during, and after VGB, and once in the controls (at approximately age 2 years). Additionally, the presence of VABAM accompanying symptoms was evaluated. Results Prevalence of VABAM in VGB‐treated TSC patients was 35.5%. VABAM‐like abnormalities were observed in 13.5% of all patients without VGB. VGB was significantly associated with VABAM (risk ratio [RR] = 3.57, 95% confidence interval [CI] = 1.43–6.39), whereas TSC and refractory epilepsy were not. In all 13 VGB‐treated patients with VABAM for whom posttreatment MRIs were available, VABAM entirely resolved after VGB discontinuation. The prevalence of symptoms was 11.7% in patients with VABAM or VABAM‐like MRI abnormalities and 4.3% in those without, implicating no significant association (RR = 2.76, 95% CI = .68–8.77). Significance VABAM are common in VGB‐treated TSC infants; however, VABAM‐like abnormalities also occurred in children without either VGB or TSC. The cause of these MRI changes is unknown. Possible contributing factors are abnormal myelination, underlying etiology, recurrent seizures, and other antiseizure medication. Furthermore, the presence of VABAM (or VABAM‐like abnormalities) did not appear to be associated with clinical symptoms. This study confirms that the well‐known antiseizure effects of VGB outweigh the risk of VABAM and related symptoms.
clinical neurology